The Center for Drug Evaluations of the National Medical Products Administration (NMPA) in China has accepted the biologics license application (BLA) for zanidat 11 June 2024
UK pharma major GSK (LSE: GSK) and US biotech SpringWorks Therapeutics are to end their collaboration combining Blenrep (belantamab mafodotin) and Ogsiveo (niro 11 June 2024
Biotechnology startup Alumis is set to go public, filing with the US Securities and Exchange Commission for an initial public offering (IPO). 11 June 2024
I-Mab has appointed Phillip Dennis as chief medical officer, overseeing the company's global clinical development efforts and joining the executive leadership t 7 June 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.